3 Healthcare Stocks That Have Held Up in Every Market Downturn

The article highlights Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson as recession-resistant healthcare leaders with long dividend histories and recurring revenue. J&J reported 2025 trailing net profit margin of 28.5% versus 15.8% in 2024 and guides to 2026 revenue of $99.5B-$100.5B; Abbott reported 2025 sales of $44.3B and expects 2026 EPS of $5.55-$5.80; Becton Dickinson reported Q1 2026 revenue of $5.3B and sees low-single-digit growth for 2026. Offseting the positive fundamentals are ongoing legal and regulatory risks, including talc suits at J&J, formula litigation at Abbott, and FDA scrutiny at Becton Dickinson.

Analysis

The market is re-pricing a narrow slice of defensive healthcare as a quasi-macro hedge, but the real opportunity is not simply “own defensives” — it is to own the names with the best litigation-adjusted compounding power. JNJ looks best positioned because the post-spinoff mix shift has mechanically improved capital efficiency; that matters more than headline revenue in a late-cycle tape because it supports dividend growth and buybacks without stretching leverage. ABT has the cleanest earnings elasticity if growth slows, since its portfolio can rotate toward faster-growing diagnostics/devices when consumables or procedure-linked demand softens.

BDX is the most interesting second-order beneficiary because its revenue quality is anchored in consumables that hospitals cannot defer, which makes it a natural winner if we get a slowdown in elective procedures without a broad collapse in healthcare utilization. That said, BDX carries more regulatory overhang than the market is likely discounting; if FDA scrutiny escalates, multiple compression can overwhelm the defensive earnings profile. In other words, BDX is a good operating business but a less clean stock to hide in than JNJ/ABT over the next 3-6 months.

The contrarian read is that the “Dividend King recession outperformance” framing may already be partially crowded. These names tend to get bid early in risk-off regimes, so the entry point matters more than the thesis. The biggest reversal trigger would be a headline risk event that does not hit earnings immediately but changes policy expectations — especially drug pricing or litigation updates — because these stocks are valued on durability, and any impairment to that perception can drive a faster de-rating than fundamentals alone would justify.

Key Decisions for Investors

• Long JNJ vs. short XLF or IWM for a 3-6 month defensive pair trade; thesis is lower earnings volatility plus better capital return support if macro growth rolls over. Target 8-12% relative outperformance, stop if recession odds fall materially and cyclicals re-accelerate.
• Add ABT on pullbacks over the next 2-4 weeks; use it as the cleaner healthcare quality compounder with the best balance of organic growth and dividend support. Upside is mid-single-digit absolute with downside cushioned by recurring product mix.
• Avoid aggressive fresh longs in BDX until regulatory noise clears; if already owned, hedge with a partial short via XLV put spread or reduce into strength. Risk/reward is less attractive because a compliance headline could compress the multiple 10-15% even if fundamentals remain stable.
• Buy JNJ 6-9 month call spreads instead of outright equity if looking for convexity around litigation/price negotiation headlines. This caps premium outlay while keeping exposure to a rerating if legal overhang proves less severe than feared.
• Use any broad market selloff to rotate from lower-quality defensives into JNJ/ABT rather than chasing them after the move. These names typically outperform on a lag, so entry after initial risk-off is usually better than front-running the fear trade.